Health Care • Biotechnology: Commercial Physical & Biological Resarch
$0.79 ▼ -0.08
(-9.35%)
MKT CAP: $2.0M • VOL: 2.59M
52W L $1 52W H $33
ROARABLE / RQD
E • 30/100
PIOTROSKI
3 / 9
ISPC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.9M | $9.3M | $9.9M |
| YoY Revenue Growth % | -79.2% | -6.4% | — |
| Gross Profit | $215.7K | $4.2M | — |
| Gross Margin % | 11.2% | 45.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.0M | -$12.7M | -$11.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$10.5M | -$12.5M | -$11.1M |
| EBITDA (Normalized) | -$9.0M | -$12.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$4.2M | -$8.3M | -$5.8M |
| Capital Expenditures (CapEx) | $454 | $31.5K | — |
| Free Cash Flow (FCF) | -$4.2M | -$8.3M | -$5.8M |
| FCF Margin % | -80.0% | -80.0% | -58.5% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $6.9M | $1.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $3.1M | $3.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ISPC.